No Data
Hong Kong stocks movement | HUA MEDICINE-B (02552) rose nearly 30% in the afternoon. The company has built its own sales team to advance the commercialization process of Huadongning.
HUA MEDICINE-B (02552) rose nearly 30% in the afternoon, as of the time of writing, it rose by 24.12%, trading at 2.11 Hong Kong dollars, with a transaction volume of 20.8871 million Hong Kong dollars.
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
HUA MEDICINE-B (02552): HUA MEDICINE Shanghai formally delivered a termination notice to Bayer according to the agreement.
HUA MEDICINE-B (02552) announced that on December 31, 2024, HUA MEDICINE in Shanghai will, according to the agreement, supply to Ba...
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Is Hua Medicine (Shanghai) (HKG:2552) Using Debt In A Risky Way?